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INTRODUCTION: Substantial controversy exists regarding the association between testosterone serum levels and
prostate cancer.
OBJECTIVE: To evaluate the levels of hypothalamic-pituitary-testicular axis hormones in the sera of men with
prostate cancer and atypical small acinar proliferation as well as those with normal biopsies.
METHODS: A study cohort of 186 men with suspected prostate cancer who had undergone transrectal prostate
biopsies was used in this study. The patients were divided into the following three groups based on the histology of
the biopsy samples: no neoplasia, atypical small acinar proliferation or prostate cancer. Demographic data were also
collected. Levels of total testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and
serum prostate-specific antigen were measured in blood samples.
RESULTS: Initially, 123 men were found to be without neoplasia, 26 with atypical small acinar proliferation and 37
with prostate cancer. After a second biopsy was taken from the men diagnosed with atypical small acinar
proliferation, the diagnoses were revised: 18 were diagnosed with atypical small acinar proliferation and 45 with
prostate cancer. No significant differences between the groups were identified regarding age, smoking history,
chronic diseases, body mass index or PSA levels (P.0.05). The mean serum levels of testosterone, follicle-stimulating
hormone, luteinizing hormone, prolactin and estradiol were similar in all of the groups (P.0.05). Furthermore, in
individuals with prostate cancer, the Gleason scores and prevalence of hypogonadism were not significantly
different (P.0.05).
CONCLUSION: The present study revealed no difference in the serum levels of testosterone, follicle-stimulating
hormone, luteinizing hormone, prolactin or estradiol in men without neoplasia compared with those with atypical
small acinar proliferation or prostate cancer.
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INTRODUCTION
Prostate cancer is the second most frequent malign
neoplasia in the world, as well as the most frequent tumor
affecting men except non-melanoma skin tumors.1,2 The
etiology of prostate neoplasia is unknown, although some
risk factors have been determined like familiar history, age
and race. The androgens, specifically testosterone, have a
fundamental role in the growth of the prostate gland.3 In the
1940s, Huggins and Hodges4 demonstrated that, in men
with advanced prostate cancer, androgenic deprivation
caused tumor regression. This observation causes some
concern regarding the possibility of the potential role of
androgens as an etiologic factor in the development of
prostate cancer. However, most epidemiologic studies were
unable to establish a consistent relationship between higher
androgen serum levels as a risk factor for prostate cancer.
Interestingly, the Prostate Cancer Prevention Trial (PCPT)5
revealed that finasteride, an 5a-redutase inhibitor, admin-
istration reduced prostate cancer diagnoses by 25% after
seven years of treatment. Although, in this same trial, the
occurrence of higher grades of prostate cancer in the
finasteride group, when compared to the control group,
was unexpected and intriguing.
Furthermore, other publications have demonstrated that
low testosterone serum levels was associated with undiffer-
entiated tumors,6 advanced tumor stage7 and unfavorable
prognosis after radical prostate surgery.8 All of these
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observations revealed that the relationship between prostate
cancer and testosterone is far from a complete under-
standing requiring further investigation.
Some prostate biopsy characteristics such as, prostate
intra-epithelial neoplasia and, more recently, atypical small
acinar proliferation (ASAP) have been implicated as
prostate cancer risk factors during follow-up of those
patients.9 The role of serum hormones, including the
androgens, in patients with ASAP or prostate cancer, has
not been explored yet, but might be helpful to improve our
understanding of the relationship between the hormones
from hypothalamic-pituitary-testicular axis in men with or
without prostate cancer.
Based on the discussion above, the objective of the current
study is to evaluate serum levels of the hypothalamic-
pituitary-testicular axis hormones in men submitted to
prostate biopsies and histological characteristics of ASAP,
prostate cancer and negative results.
MATERIALS AND METHODS
Study Population
All men visiting the Urology Division of Santa Casa
Hospital of Porto Alegre, Brazil, between March 2006 and
December 2007 with indication of prostate biopsy were
invited to participate in this study. A prostate biopsy was
indicated if the serum prostate specific antigen (PSA) was
over 2.5 ng/ml or had increased by more than 0.75 ng/ml/
year, and/or suspicious results from a digital rectal exam of
the prostate gland (prostatic lobe asymmetry, nodules or
altered consistency). Exclusion criteria included previous or
current use of testosterone replacement therapy, previous
prostate surgery, urinary infection or other inflammatory
or infectious condition affecting the genito-urinary tract,
current use of a vesical catheter and chemotherapy or
radiotherapy for treatment of pelvic neoplasia.
Of the 437 men evaluated during this period, all signed an
informed consent form. The study was approved by the
Research Ethics Committee of the Institution.
Men fulfilling the inclusion criteria were interviewed
approximately 30 days before the prostate biopsy by two of
the authors (CSS and GLA) to collect the data. Weight and
height were checked using a scale calibrated previously
(FilizolaH, Sao Paulo, Brazil) and the body mass index (BMI)
was calculated by dividing the weight (Kg) by the square of
the height (m2). The individuals themselves classified their
race as Caucasian or not Caucasian. Also during this
interview, individual data about medical history were
collected, such as previous surgery, acute and chronic
diseases, medications and smoking. After the interview, the
patients were sent to the laboratory to have a blood sample
drawn and then to their scheduled prostate biopsy date.
Biochemical Analysis
After four hours fasting,10 a venous blood sample was
obtained between 7 and 11 am, to assess serum levels of
total testosterone (TT), follicle-stimulating hormone (FSH),
luteinizing hormone (LH), prolactin and estradiol. Serum
levels of TT (normal range: 241 to 827 ng/dL), FSH (normal
range: 1.4 to 18.1 mIU/mL), LH (normal range: 1.5 to
9.3 mIU/mL) and prolactin (normal range: 2.1 to 17.7 ng/
mL) were determined by electrochemiluminescence using
the ADVIA Centaur 2000 system (SiemensH, Sao Paulo,
Brazil), while estradiol (normal range: up to 56.0 pg/mL)
and total PSA (normal range: up to 2.5 ng/mL) were
determined by the Immulite immunometric chemilumines-
cent method (Diagnostic Products Corp, Los Angeles, CA,
USA).
Prostate biopsy
An ultrasound-guided transrectal biopsy was performed
by standard methods using a Tosbee 4 endocavity trans-
ductor (ToshibaH, New York, USA) under local anesthesia
(20 mL of 1% lidocain injected bilaterally around the
neurovascular bundle).11 A mean of twelve biopsy cores
were removed from each prostate gland, but this number
was exceeded when indicated by the presence of a nodule or
other suspect image on ultrasound. The tissue samples were
stored in bottles containing 10% of formalin.
Histological examination of the prostate
Microscopically, all samples isolated by biopsy were
analyzed, after staining with hematoxylin and eosin using
standard laboratory methods, by a single expert pathologist
of our Institution.
The individuals were divided into three groups according
to the histological results: without neoplasia (including
benign prostate hyperplasia, acinar atrophy and high grade
prostate intra-epithelial neoplasia), ASAP and prostate
cancer. Men diagnosed with ASAP by biopsy were
subjected to a second biopsy. These results were used to
newly diagnose men with prostate cancer, while the others
remained in the ASAP group.
Complicating factors
Potential complicating factors that could interfere with
serum TT levels were measured to avoid false results,
including age, obesity, smoking, chronic diseases such as
hypertension, diabetes, peripheral vascular disease,
ischemic heart disease, dyslipidemia and hyperthyroidism,
and serum levels of other hormones of the hypothalamic-
pituitary-testicular axis like FSH, LH, prolactin and estra-
diol. We did not include free testosterone serum levels in
the current study by protocol and laboratory difficulties.
Statistical analysis
Data like smoking, race and chronic disease were
analyzed with the Chi-square test. The same test was
applied when a stratified analysis was done using the
hypogonadism criteria for patients with serum TT under
300 ng/mL. To evaluate the effect of age, BMI and some of
the hormones (TT, prolactin and estradiol), ANOVA was
used, and for the total PSA, FSH and LH we used a non-
parametric test (Kruskal-Wallis). Results were considered
statistically significant when the P value was less than 0.05.
All analyses were done using the SPSS statistical program,
version 14.0 for Windows (SPSS, Chicago, IL, USA).
RESULTS
After screening, 186 men who had indication for prostate
biopsy, based on current protocol, were eligible for analyses.
The mean age of the study population was 64.54¡ 6.7 years
(range: 47 to 80 years). Of the participants, 75.8% identified
themselves as Caucasian. The median total PSA serum level
was 6.17 ng/mL (range: 0.2 to 188.0 ng/mL). The mean TT
concentration was 413.43 ¡ 142.6 ng/dL (range: 80 to
954 ng/dL). Of the 186 patients, 123 (66.1%) were diagnosed
Testosterone and Prostate Cancer
Schmitt CS et al.
CLINICS 2011;66(2):183-187
184
as no neoplasia, 26 (14%) with ASAP and 37 (19.9%) with
prostate cancer. Overall, 57 (30.6%) of the individuals
presented at least one associated medical condition repre-
sented by dyslipidemia (30.6%), hypertension (24.7%),
diabetes mellitus (17.7%), peripheral vascular disease
(10.2%), ischemic heart disease (8.6%) and hyperthyroidism
(1.6%). Other data are described in Table 1.
Subsequent analyses divided the patients according to the
histological results: without neoplasia, ASAP and prostate
cancer. Men with ASAP on the first biopsy but prostate
cancer on the second biopsy, 8 (31%) cases, were re-
allocated by the second result. The groups do not differ in
relation to age (P= 0.37), BMI (P= 0.66), race (P=0.36),
smoking (P=0.79) or the presence of a chronic disease
(P= 0.27), as well as the median total PSA serum level (6.05
vs. 5.63 vs. 6.63 ng/mL, respectively; P= 0.22; Table 2).
The mean TT serum level were respectively 414.4
¡ 147.33 ng/dL for patients without neoplasia, 421.17 ¡
149.24 ng/dL for patients with ASAP, and 408.40 ¡
129.05 ng/dL for patients with prostate cancer (P=0.95).
The other hormones (FSH, LH, prolactin and estradiol) were
similar among the different studied groups (P.0.05; Table 3).
Analysis of the prostate cancer group revealed no
correlation between stratified Gleason score (# 6, 7 and $
8) and TT (P= 0.59), FSH (P= 0.91), LH (P=0.49), prolactin
(P= 0.59) or estradiol (P= 0.42), however the median total
PSA serum level was higher in the group of men with the
highest Gleason score (P=0.01; Table 4).
When men were differentiated between low TT (less than
300 ng/mL) and those with normal TT (more than 300 ng/
dL), we did not find a statistically difference regarding the
histological groups. The prevalence of men with levels of TT
less than 300 ng/mL was 24.4% in the group without
neoplasia, 33.3% in the ASAP group, and 22.2% in the
prostate cancer group (P= 0.65).
DISCUSSION
The present study included a homogeneous group of men
with similar characteristics that can influence androgen
levels such as age, BMI, history of smoking, and chronic
diseases. The median total PSA serum level did not differ
Table 1 - General characteristics of the study population.
Individuals { 186 (100)
Age (years) { 64.54 (6.71)
Body Mass Index (kg/m2) { 27.25 (4.71)
Chronic Diseases (present) { 94 (50.5)
Caucasians { 141 (75.8)
Smoking { 21 (11.3)
Total PSA (ng/mL) h 6.17 (4.64-9.25)
FSH (mIU/mL) h 5.70 (4.10-8.75)
LH (mIU/mL) h 4.20 (2.90-6.12)
Estradiol (pg/mL) { 21.47 (7.16)
Prolactin (ng/mL) { 5.77 (2.79)
Total Testosterone (ng/dL) { 413.43 (142.6)
Prostate biopsy result: {*
Without neoplasia 123 (66.1)
ASAP 26 (14)
Prostate cancer 37 (19.9)
{: N and %;
{: Mean and standard deviation;
h: Median (percentile 25-75)
*: Results before the second biopsy of the first ASAP
ASAP: atypical small acinar proliferation
Table 2 - Men categorized according to the prostate biopsy result: without neoplasia, ASAP and prostate cancer.
Prostate biopsy
Without neoplasia ASAP Prostate cancer P value
Individuals { 123 (66.1) 18 (9.7) 45 (24.2)
Age (years) { 64.3 ¡ 6.6 66.2 ¡ 5.5 64.0 ¡ 7.6 0.37
Caucasians { 94 (77.7) 11 (69.2) 36 (78.4) 0.36
BMI (kg/m2) { 27.2 ¡ 4.2 26.6 ¡ 6.2 27.7 ¡ 4.9 0.66
Chronic disease { (present) 67 (54.5) 7 (38.5) 20 (45.9) 0.27
Smoking { 15 (12.2) 2 (11.5) 4 (8.1) 0.79
Total PSA (ng/mL) h 6.05 (4.58-9.06) 5.63 (4.36-7.42) 6.63 (5.10-10.95) 0.22
{: N (%);
{: Mean ¡ standard deviation;
h: Median (percentile 25-75)
ASAP: atypical small acinar proliferation
Table 3 - Serum total testosterone (TT), follicle stimulant hormone (FSH), luteinizing hormone (LH), prolactin and
estradiol levels in men diagnosed by prostate biopsy as without neoplasia, or ASAP or prostate cancer.
Prostate biopsy
Without neoplasia (N = 123) ASAP (N = 18) Prostate cancer (N = 45) P value
TT (ng/mL) { 414.14 (387.84-440.44) 421.17 (346.95-495.38) 408.40 (369.63-447.17) 0.95
FSH (mIU/mL) h 6.00 (3.90-8.50) 5.60 (4.30-12.07) 5.20 (4.20-8.65) 0.86
LH (mIU/mL) h 4.10 (2.70-6.00) 4.65 (2.72-5.45) 4.50 (3.35-6.00) 0.58
Prolactin (ng/mL) { 5.62 (5.21-6.04) 6.04 (3.72-8.37) 6.07 (5.17-6.98) 0.59
Estradiol (pg/mL) { 21.06 (19.83-22.28) 20.79 (16.36-25.22) 22.86 (20.69-25.03) 0.32
{: Mean ¡ standard deviation;
h: Median (percentile 25-75)
ASAP: atypical small acinar proliferation
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significantly among men without prostate cancer, ASAP or
with prostate cancer. Importantly the mean TT serum level
in men with negative prostate biopsy was similar to those
individuals diagnosed with ASAP or prostate cancer.
Furthermore, the other hormones evaluated as FSH, LH,
prolactin and estradiol, also did not differ between the three
studied groups. In relation to the Gleason score of the
prostate cancer group, no significant differences could be
established regarding the mean serum levels of the
hormones of hypothalamic-pituitary-testicular axis, includ-
ing total testosterone. In addition, there was no statistically
significant difference in the prevalence of hypogonadal
serum levels of TT (considered as less than 300 ng/dL)
between the study groups.
Recently, several authors12-14 have directed their attention
trying to understand the relationship between total testoster-
one serum levels and prostate cancer. Epidemiological
studies have presented controversial results, with some
showing a positive relationship between testosterone levels
and a higher risk of prostate cancer,15 but most demonstrat-
ing that this relationship could not be verified conclusively or
was negative.16 More recently, a pooled database covering
18 prospective studies,17 published by the Endogenous
Hormones and Prostate Collaborative Group, which enrolled
3886 men with prostate cancer and 6438 controls, was unable
to demonstrate a significant relationship between serum TT
and free testosterone levels, or its metabolites, or even serum
levels of other androgens, like dehydroepiandrosterone
sulfate and androstenedione, and a higher risk of prostate
cancer, even after they were grouped by quintiles of serum
concentrations. In this same study, the Gleason score of
prostate cancer cases as well as tumor stage did not correlate
with either low or elevated serum levels of androgens or their
metabolites. It is interesting that this pooled database
included 95% of the available data in the world regarding
this topic. Based in this context, the current study data
suggest, even with a modest number of men, an inconsistent
relationship between serum testosterone levels and prostate
cancer diagnosed in a clinical setting. The broad variation in
TT serum levels could partially explain the lack of difference
observed in our study. Although, even when men were
classified as having normal or subnormal TT level using a
standard cutoff point (300 ng/dL) from the literature,10 the
histological findings were similar between groups.
However, recent new studies18-20 have demonstrated a
positive correlation between men with more undifferen-
tiated prostate cancer with subnormal TT serum levels, the
results of the current analysis are consistent with data from
other studies,21,22 which demonstrates that this correlation is
not established and most likely depends on the patients
characteristics, as well as the technique used to measure
serum TT, the type of analysis performed and whether or
not potential complicating factors were eliminated from the
analysis. Also, it is interesting to observe that the majority of
these studies are based in retrospective analyses which has
several methodological limitations.
The relationship between hypothalamic-pituitary-
testicular axis hormonal levels and prostate cancer was
initially suggested by Miller and colleagues23 and, subse-
quently, by Madersbacher and colleagues.24 Hypothetically,
the tumor or a tumor cell product could inhibit androgen
production, thereby suppressing the release of hypothala-
mic-pituitary hormones and, consequently, testicular ster-
oidogenesis. Though clinical studies have demonstrated
that removing prostate cancer results in an elevation of FSH,
LH and testosterone, the mechanism of this response
remains to be clarified.23,24 In the current study, we did
not find that hypothalamic-pituitary-testicular axis hormo-
nal levels were different independent of the diagnosis, even
with ASAP or prostate cancer.
Perhaps the most important contribution of the present
study is the inclusion of men with the diagnosis of ASAP, a
condition frequently correlated to a concomitant or a sub-
sequent prostate cancer diagnosis.9 It is well established that
ASAP is a histological prostate alteration that not fill out the
characteristics for the diagnosis of prostate cancer. A study in
whichmendiagnosedwithASAP had a radical prostatectomy
revealed that all 25 (100%) patients had a final histological
diagnosis of prostate cancer from the surgical specimen.25 For
researchers investigating whether prostate cancer is related to
higher levels of total testosterone, this is the best population to
study since this condition is increasingly considered as a risk
factor for prostate cancer. Although, in the current study,
serum levels of all hormones of the hypothalamic-pituitary-
testicular axis were similar. It is important to point out that
there is a lack of data in the literature regarding androgen
levels in men with ASAP, which limits discussions or
comparisons based in the results of other studies.
Certainly the relationship between prostate cancer and
testosterone is complex and requires further investigation.
The hypothesis that higher serum levels of testosterone
increases prostate cancer risk was originated in the observa-
tion that established prostate cancer regresses after surgical
or medical castration.4 However, this occurs in advanced
Table 4 - Serum total prostatic specific antigen (PSA) and hypothalamic-pituitary-testicular axis hormones levels in men
with prostate cancer, categorized by Gleason score.
Gleason score
# 6 7 $ 8 P value
N (%) 18 (40) 19 (42.3) 8 (17.7)
Total PSA (ng/mL)h 5.78 (4.61-6.47) 7.35 (6.16-16.85) 15.32* (10.00-21.90) 0.01
TT (ng/mL) { 393.56 (333.36-453.75) 431.74 (358.39-505.08) 386.38 (316.61-456.14) 0.59
FSH (mIU/mL) h 8.33 (3.52-13.14) 7.82 (4.89-10.75) 9.23 (1.84-16.62) 0.91
LH (mIU/mL) h 8.66 (0.59-16.74) 5.18 (3.87-6.49) 4.30 (3.29-5.30) 0.49
Estradiol (pg/mL) { 21.61 (18.36-24.87) 22.84 (19.71-25.98) 25.70 (17.31-34.10) 0.42
Prolactin (ng/mL) { 6.06 (4.92-7.20) 6.47 (4.54-8.40) 5.15 (3.94-6.36) 0.59
{: Mean ¡ standard deviation;
h: Median (percentile 25-75)
*In relation to the other groups
Testosterone and Prostate Cancer
Schmitt CS et al.
CLINICS 2011;66(2):183-187
186
tumors and may not correspond to lower stage prostate
tumors, especially when studying the etiology of the prostate
cancer. Recently, in an elegant publication, Morgentaler and
Traish26 suggested The Saturation Theory as explanation for
some of the controversial data regarding the issue of prostate
and testosterone levels. Based in this theory, testosterone
serum levels just over the levels of a castrated condition
would have the maximum possible androgen effect, since all
the prostate cell receptors would be occupied by androgens
or their metabolites. Also, this theory would differentiate the
effects of testosterone based on the individual androgen
status. In the clinical field, this theory also could be a
reasonable explanation for the negative results of the current
data as well as for the majority epidemiological studies,
especially those with negative results regarding testosterone
and risk of prostate cancer.26
Maybe one of the most important complicating factor of all
studies published in literature which tried to establish some
relationship regarding androgens and prostate cancer, includ-
ing the current study, is the fact that TT serum levels do not
necessarily reflect the androgenic activity inside the prostate
gland. Certainly, the most important factor related to this
observation is the fact that dihydrotestosterone, the active
metabolite of the testosterone, is converted in the prostate
tissue, and not in the bloodstream. The direct observation of
this metabolic aspect is the fact that serum levels of androgens
may not correlate with the active hormonal environment
inside the prostate gland. Furthermore, natural variations in
the production of hormones on a daily basis, as well as
variation in serum hormone level measurement techniques
between laboratories, should be also considered.
Other limitations of the present study need to be
considered. The most relevant limitations are the number of
patients and the single measurement of the different
hormones. A single dosage of serum testosterone may not
represent properly the hormone exposure of that person
during his life.27 However, well-defined inclusion criteria, as
well as selection of cases based on the usually recommended
indication of prostate biopsy and the prospective nature of
the study as well as including individuals with normal
biopsies, should reduce potential selection bias. Other
authors18,21 included free or bioavailable testosterone levels
in their studies regarding this issue. Unfortunately, in the
current study these analyses were not included as explained
initially. Although, based in the Endogenous Hormones and
Prostate Collaborative Group publication17 and also in the
observation that the study population presented similar
characteristics regarding factors that may influence testoster-
one levels we would not expect significant different results.
In conclusion, our study did not demonstrate different
serum levels of TT, FSH, LH, prolactin and estradiol in men
with prostate biopsy without neoplasia, ASAP or prostate
cancer.
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